Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-22-ab003/coif). STHP and MH are members of the Dutch guidelines about thymic tumors. FM reports that she is an unpaid committee member of Dutch Rare Cancer Platform and Dutch guidelines about Thymic Tumors. The other authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
Cite this abstract as: Peeters STH, Kneepkens E, Marcuse F, Zhang X, Hochstenbag M, Maessen J, Ruysscher DD. Benefits of proton radiotherapy in thymic epithelial tumors using the model-based approach. Mediastinum 2022;6:AB003.